Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy

      research-article
      , PhD 1 , , PhD, FRCPath 2 , , MD, PhD 3 , , MD 4 , , MD 5 , , MD, PhD 6 , , MD 7 , , MD 8 , , MD, PhD 9 , 10 , 12 , , MD 13 , , PhD, FRCPath 14 , , PhD 15 , 16 , , PhD 15 , , PhD 12 , , MD 9 , 11 , 12 , , MD 11 , 12 , , PhD 11 , 12 , , MD 9 , 10 , 11 , 12 , the TBI/CTE Research Group
      Journal of Neuropathology and Experimental Neurology
      Oxford University Press
      Brain trauma, Chronic traumatic encephalopathy, Neurodegenerative disorders, Tauopathy, Traumatic brain injury

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder associated with exposure to head trauma. In 2015, a panel of neuropathologists funded by the NINDS/NIBIB defined preliminary consensus neuropathological criteria for CTE, including the pathognomonic lesion of CTE as “an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical sulci and in an irregular pattern,” based on review of 25 tauopathy cases. In 2016, the consensus panel met again to review and refine the preliminary criteria, with consideration around the minimum threshold for diagnosis and the reproducibility of a proposed pathological staging scheme. Eight neuropathologists evaluated 27 cases of tauopathies (17 CTE cases), blinded to clinical and demographic information. Generalized estimating equation analyses showed a statistically significant association between the raters and CTE diagnosis for both the blinded (OR = 72.11, 95% CI = 19.5–267.0) and unblinded rounds (OR = 256.91, 95% CI = 63.6–1558.6). Based on the challenges in assigning CTE stage, the panel proposed a working protocol including a minimum threshold for CTE diagnosis and an algorithm for the assessment of CTE severity as “Low CTE” or “High CTE” for use in future clinical, pathological, and molecular studies.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Neuropathological stageing of Alzheimer-related changes

          Eighty-three brains obtained at autopsy from nondemented and demented individuals were examined for extracellular amyloid deposits and intraneuronal neurofibrillary changes. The distribution pattern and packing density of amyloid deposits turned out to be of limited significance for differentiation of neuropathological stages. Neurofibrillary changes occurred in the form of neuritic plaques, neurofibrillary tangles and neuropil threads. The distribution of neuritic plaques varied widely not only within architectonic units but also from one individual to another. Neurofibrillary tangles and neuropil threads, in contrast, exhibited a characteristic distribution pattern permitting the differentiation of six stages. The first two stages were characterized by an either mild or severe alteration of the transentorhinal layer Pre-alpha (transentorhinal stages I-II). The two forms of limbic stages (stages III-IV) were marked by a conspicuous affection of layer Pre-alpha in both transentorhinal region and proper entorhinal cortex. In addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the two isocortical stages (stages V-VI) was the destruction of virtually all isocortical association areas. The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

            We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Primary age-related tauopathy (PART): a common pathology associated with human aging.

              We recommend a new term, "primary age-related tauopathy" (PART), to describe a pathology that is commonly observed in the brains of aged individuals. Many autopsy studies have reported brains with neurofibrillary tangles (NFTs) that are indistinguishable from those of Alzheimer's disease (AD), in the absence of amyloid (Aβ) plaques. For these "NFT+/Aβ-" brains, for which formal criteria for AD neuropathologic changes are not met, the NFTs are mostly restricted to structures in the medial temporal lobe, basal forebrain, brainstem, and olfactory areas (bulb and cortex). Symptoms in persons with PART usually range from normal to amnestic cognitive changes, with only a minority exhibiting profound impairment. Because cognitive impairment is often mild, existing clinicopathologic designations, such as "tangle-only dementia" and "tangle-predominant senile dementia", are imprecise and not appropriate for most subjects. PART is almost universally detectable at autopsy among elderly individuals, yet this pathological process cannot be specifically identified pre-mortem at the present time. Improved biomarkers and tau imaging may enable diagnosis of PART in clinical settings in the future. Indeed, recent studies have identified a common biomarker profile consisting of temporal lobe atrophy and tauopathy without evidence of Aβ accumulation. For both researchers and clinicians, a revised nomenclature will raise awareness of this extremely common pathologic change while providing a conceptual foundation for future studies. Prior reports that have elucidated features of the pathologic entity we refer to as PART are discussed, and working neuropathological diagnostic criteria are proposed.
                Bookmark

                Author and article information

                Journal
                J Neuropathol Exp Neurol
                J Neuropathol Exp Neurol
                jnen
                Journal of Neuropathology and Experimental Neurology
                Oxford University Press
                0022-3069
                1554-6578
                March 2021
                21 February 2021
                21 February 2021
                : 80
                : 3
                : 210-219
                Affiliations
                [1 ] Department of Pathology, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, UT Health San Antonio , San Antonio, Texas
                [2 ] Department of Neurology, Washington University School of Medicine , Saint Louis, Missouri
                [3 ] Departments of Pathology & Neuroscience, Ronald M. Loeb Center for Alzheimer’s Disease, Freidman Brain Institute, Icahn School of Medicine at Mount Sinai School , New York, New York
                [4 ] Department of Neuroscience, Mayo Clinic , Jacksonville, Florida
                [5 ] New York City Office of Chief Medical Examiner and Department of Forensic Medicine, New York University School of Medicine , New York, New York
                [6 ] Department of Pathology, University of Washington School of Medicine , Seattle, Washington
                [7 ] Department of Neurosciences, University of California San Diego School of Medicine , La Jolla, California
                [8 ] Department of Pathology, Uniformed Services University of the Health Sciences , Bethesda, Maryland
                [9 ] VA Boston Healthcare System , Boston, Massachusetts
                [10 ] Department of Pathology, Boston University School of Medicine, Boston, Massachusetts; Department of Veteran Affairs Medical Center , Bedford, Massachusetts
                [11 ] Department of Neurology, Boston University School of Medicine, Boston, Massachusetts; Department of Veteran Affairs Medical Center , Bedford, Massachusetts
                [12 ] Alzheimer's Disease Center, CTE Program, Boston University School of Medicine, Boston, Massachusetts; Department of Veteran Affairs Medical Center , Bedford, Massachusetts
                [13 ] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center , New York, New York
                [14 ] Department of Neuropathology, University of Glasgow Institute of Neuroscience and Psychology and Queen Elizabeth University Hospital , Glasgow, United Kingdom
                [15 ] Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai , New York, New York
                [16 ] Department of Neurology (KD-O), Icahn School of Medicine at Mount Sinai , New York, New York
                Author notes
                Send correspondence to: Ann C. McKee, MD, Boston University School of Medicine, 72 East Concord Street, Robinson 7800, Boston, MA 02118; E-mail: amckee@ 123456bu.edu
                Article
                nlab001
                10.1093/jnen/nlab001
                7899277
                33611507
                392a9f53-3133-4399-9a22-be2331c738f8
                © 2021 American Association of Neuropathologists, Inc.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                Page count
                Pages: 10
                Funding
                Funded by: National Institute of Neurological Disorders and Stroke, DOI 10.13039/100000065;
                Award ID: 1U01NS086659-01
                Award ID: 1U01NS086625-01
                Award ID: R01NS078337
                Award ID: R56NS078337
                Award ID: R01NS095252
                Funded by: Department of Defense, DOI 10.13039/100000005;
                Award ID: W81XWH-13-2-0064
                Award ID: W81XWH-14-1-0399
                Funded by: Department of Veterans Affairs, the Veterans Affairs Biorepository;
                Award ID: CSP 501
                Funded by: National Institute of Aging;
                Award ID: 1R01AG061028-01
                Funded by: National Institute of Aging Boston University Alzheimer’s Disease Center;
                Award ID: P30AG13846
                Award ID: 0572063345-5
                Funded by: Department of Defense Peer Reviewed Alzheimer’s Research Program;
                Award ID: DoD-PRARP #13267017
                Funded by: National Institute of Aging Boston University Framingham Heart Study;
                Award ID: R01AG1649
                Funded by: National Operating Committee on Standards for Athletic Equipment, DOI 10.13039/100005636;
                Funded by: Concussion Legacy Foundation;
                Funded by: Andlinger Foundation;
                Funded by: World Wrestling Entertainment;
                Funded by: National Football League;
                Award ID: P50 AG05681
                Award ID: P01 AG03991
                Funded by: National Institute on Aging, DOI 10.13039/100000049;
                Categories
                Original Articles
                AcademicSubjects/MED00994

                brain trauma,chronic traumatic encephalopathy,neurodegenerative disorders,tauopathy,traumatic brain injury

                Comments

                Comment on this article